<DOC>
	<DOCNO>NCT03036943</DOCNO>
	<brief_summary>The purpose study find new amino acid-based PET agent , fluciclovine ( 18F ) , tell u breast cancer biology ( grows develops ) , quantify difference fluciclovine ( 18F ) uptake breast cancer subtypes . This inform work investigate use breast cancer management .</brief_summary>
	<brief_title>Fluciclovine ( 18F ) Imaging Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Biopsy proven , clinically palpable breast cancer ( invasive ductal ductal carcinoma situ ( DCIS ) ) measure â‰¥ 2cm schedule treated primary surgical resection Tumour size base long diameter measure ultrasound , mammogram MRI perform within 2 month prior enrolment . 2 . No prior treatment breast cancer . 3 . Female , Age &gt; = 50 year . 4 . The patient reach menopause , define age group amenorrhoea least 12 month . 5 . The patient willing able comply protocol schedule visit examination duration study . 6 . Written ( sign date ) inform consent . 1 . Major surgery significant traumatic injury within four week prior enrolment . 2 . Treatment investigational agent , participation another interventional clinical study within 4 week prior enrolment . 3 . Multifocal and/or bilateral breast cancer 4 . Known hypersensitivity fluciclovine ( 18F ) constituent . 5 . Other psychological , social medical condition , physical examination find laboratory abnormality Investigator considers would make patient poor study candidate could interfere protocol compliance interpretation study result . 6 . Any active previous malignancy .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>